Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TELA Bio, Inc. reported revenue of $80M, up 15.8% year over year. Operating margin was -42.0% and net margin -48.4%, on a free-cash-flow margin of -35.7% with capital expenditure at 0.6% of revenue. Every figure is computed directly from TELA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $80M | -42.0% | -48.4% |
| FY2024 | $69M | -49.2% | -54.6% |
| FY2023 | $58M | -75.4% | -79.8% |
| FY2022 | $41M | -94.2% | -106.9% |
| FY2021 | $29M | -100.0% | -112.9% |
How does TELA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.